Search

Displaying results 5321 - 5330 of 7452 in total
  1. Drug

    Levonadifloxacin

    go.drugbank.com/drugs/DB16219
    Investigational

    Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Flomoxef

    go.drugbank.com/drugs/DB11935
    Investigational

    Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Target

    activator protein 1

    go.drugbank.com/bio_entities/BE0004924
    TargetHumans

    Must be down-regulated in order for such cells to exit the cycle and differentiate (By similarity). … May cooperate with the UPR transcriptional regulator QRICH1 to regulate ER protein homeostasis which is critical for cell viability in response to ER stress (PubMed:33384352).

    Polypeptides: Protein c-FosSynonyms: Proto-oncogene c-Fos, Cellular oncogene fos
  4. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Furazidin

    go.drugbank.com/drugs/DB13475
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Betamipron

    go.drugbank.com/drugs/DB19858
    Experimental

    Betamipron is a small molecule drug. Betamipron has a monoisotopic molecular weight of 193.07 Da.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  9. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is a fluorescent dye or luminescent agent.

  10. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral